<SEC-DOCUMENT>0001104659-21-065593.txt : 20210513
<SEC-HEADER>0001104659-21-065593.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513093010
ACCESSION NUMBER:		0001104659-21-065593
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		21917593

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2116118d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):
May 13, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chemomab Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as Specified in Its
Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; text-align: center"><FONT STYLE="font-size: 10pt"><B>State of Israel</B></FONT></TD>
    <TD STYLE="width: 30%; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-38807</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>81-3676773</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or Other Jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>of Incorporation)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>File Number)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 52%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Kiryat Atidim, Building 7</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 48%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Tel Aviv,&nbsp;Israel</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>6158002</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&#8217;s telephone number, including
area code: +972-77-331-0156</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed since
last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 65%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading<BR>
Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each <BR>
exchange<BR>
on&nbsp;which&nbsp;registered</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>CMMB</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital <BR>
Market</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary shares, no par value per share</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>N/A</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital <BR>
Market*</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Not for trading; only in connection with the registration of American
Depositary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;&nbsp;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities
Exchange Act of 1934 (&sect;&nbsp;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT><FONT STYLE="font-family: Wingdings"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 Results of Operations and Financial
Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 13, 2021, Chemomab
Therapeutics Ltd. issued a press release announcing its financial and operating results and recent highlights for the first quarter ended
March 31, 2021. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with General
Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not
be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Exhibit <BR>
Number</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Description</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font-size: 10pt; text-align: justify"><A HREF="tm2116118d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 88%; font-size: 10pt; text-align: justify"><A HREF="tm2116118d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press release, dated May 13, 2021 (furnished herewith pursuant to Item 2.02)</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Chemomab Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: May 13, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/ Sigal Fattal</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sigal Fattal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2116118d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99,1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-style: normal"><B><IMG SRC="tm2116118d1_ex99-1img01.jpg" ALT="">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Chemomab Therapeutics
Announces First Quarter 2021 Financial Results and Provides a Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Announced positive data from its Phase Ib SPARK
study evaluating CM-101 in NAFLD patients</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Announced first patient enrolled in two Phase
IIa studies of CM-101 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Completed merger with Anchiano Therapeutics,
and began trading on the Nasdaq Exchange under the ticker CMMB</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Cash position of $58.2 million as at March 31,
2021</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Strengthened Board of Directors with four new
appointments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TEL-AVIV, Israel, May 13, 2021 (________NEWSWIRE)
</B>-- Chemomab Therapeutics Ltd. (<FONT STYLE="color: #293849; background-color: white">Nasdaq: CMMB), </FONT>a clinical-stage biotech
company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today
announced financial and operating results for the first quarter ended March 31, 2021 and provided a business update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;This quarter has
been truly exciting for Chemomab as we accessed the public markets and began to trade on the Nasdaq exchange, successfully closed on a
private offering of $45 million, announced positive data from our Phase Ib study in NAFLD, and initiated a Phase IIa study in PSC.&rdquo;
said Dr. Adi Mor, CEO of Chemomab. &ldquo;We also started treating patients in our Phase IIa liver fibrosis trial with our subcutaneous
formulation of CM-101 and will look to build upon our substantial progress and positive momentum in the coming quarters with the initiation
of our additional planned Phase II study of CM-101 in Systemic Sclerosis (SSc). CM-101 is a very promising therapy with the potential
to treat multiple severe and life-threatening inflammatory and fibrotic diseases. With a strong financial position, and our unique development
track record we believe we are well positioned to continue to advance our pipeline and execute our important milestones this year.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>First Quarter and Recent Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Announced positive results from its Phase
Ib SPARK study evaluating CM-101 in nonalcoholic fatty liver disease (NAFLD) patients</B>. The SPARK study was a double-blind, placebo-controlled
study designed to evaluate the safety, tolerability and pharmacokinetic (PK) profile of CM-101 in NAFLD patients with normal liver function.
In this study repeated CM-101 administrations were found to be safe and well-tolerated for both tested doses when administered as intravenous
(IV) infusion or subcutaneous (SC) injection. No safety signals or unexpected adverse events were observed for CM-101 in either the IV
or SC formulation and all reported adverse events were mild or moderate in intensity. Exploratory analysis of multiple pharmacodynamic
parameters, including measurement of collagen turnover
and fibrotic biomarkers, demonstrated that CM-101 treatment resulted in reduction of fibrotic and fibrogenesis markers compared to no
change or slight elevation in the placebo treated group. In addition, there was a reduction in liver stiffness measured by FibroScan<SUP>TM</SUP>
in the CM-101 treated group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="tm2116118d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Enrolled the first patient in its Phase IIa
SPRING clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC)</B>. The SPRING study is a multi-center,
randomized, double-blind, placebo-controlled, multiple dose study designed to assess the mechanism of action, safety, pharmacokinetics
and pharmacodynamic effects, as well as the antifibrotic effect of IV CM-101 in PSC patients. The trial will enroll and randomize up to
45 patients and is anticipated to complete enrollment by early 2022 with data expected in 1H 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enrolled the first patient
in its Phase IIa SPLASH clinical trial of CM-101 for the treatment of patients with nonalcoholic steatohepatitis (NASH)</B>. The SPLASH
study is a multi-center, randomized, double-blind, placebo-controlled, multiple dose study designed to assess the mechanism of action,
safety, pharmacokinetics and pharmacodynamic effects</FONT><FONT STYLE="background-color: #FEFEFE">, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
well as the anti-fibrotic effects of SC CM-101 in NASH patients with fibrosis stage F2-F3. The trial will enroll 40 patients and is anticipated
to complete enrollment by the end of 2021 with data expected in 1H 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Completed a merger with Anchiano Therapeutics
Ltd,</B> and began trading on the Nasdaq Capital Market exchange under the symbol &ldquo;CMMB&rdquo; on March 17, 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Completed the successful pricing of a private
placement of $45 million into the combined company</B> led by new and certain existing investors including Cormorant Asset Management,
OrbiMed, Peter Thiel, Christian Angermayer&rsquo;s Presight Capital and Apeiron Investment Group, as well as other healthcare-focused
and institutional investors. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">S<B>trengthened its Board of Directors with the
appointment of four new directors</B>: Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen. Dr. Stephen Squinto remains
as Chairman of Chemomab&rsquo;s Board, with Dr. Adi Mor and Dr. Nissim Darvish continuing in their roles as Directors. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Upcoming Milestones:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Chemomab is advancing
in parallel three Phase 2 clinical trials with CM-101 in three distinct fibrotic indications; Systemic Sclerosis (SSc) is planned to be
initiated by the end of 2021, and clinical readouts from the ongoing clinical trials in PSC and NASH are expected during 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><IMG SRC="tm2116118d1_ex99-1img01.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>First Quarter 2021 Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents as of March 31, 2021
were $58.2 million which includes $45.5 million of gross proceeds from the private placement completed on March 22, 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and Development expenses for the three
months ended March 31, 2021 were $1.2 million, compared to $1.6 million for the three months ended March 31, 2020. The decrease of $0.4
million was primarily related to a decrease in expenses to sub-contractors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses were $0.5
million for the three months ended March 31, 2021, compared to $0.1 million for the three months ended March 31, 2020. The increase of
$0.4 million was primarily related to merger related expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss for the three months ended March 31,
2021 and 2020 was $1.7 million.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Chemomab Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><U>Chemomab
</U></FONT>is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related
diseases with high unmet need. Based on the unique and pivotal role of the soluble protein <U>CCL24</U> in promoting fibrosis and inflammation,
Chemomab developed <U>CM-101</U>, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple
severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for
the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For more information on Chemomab, please
visit&nbsp;<B><U>www.chemomab.com</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release
contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of
Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related
diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to
be forward-looking statements. These forward-looking statements are based upon Chemomab&rsquo;s current expectations.
Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on
Chemomab&rsquo;s current expectations, they are subject to various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation,
including: the uncertain and time-consuming regulatory approval process; risks related to Chemomab&rsquo;s ability to correctly
manage its operating expenses and its expenses; Chemomab&rsquo;s plans to develop and commercialize its product candidates, focusing
on CM-101; the timing of initiation of Chemomab&rsquo;s planned clinical trials; the timing of the availability of data from
Chemomab&rsquo;s clinical trials; the timing of any planned investigational new drug application or new drug application;
Chemomab&rsquo;s plans to research, develop and commercialize its current and future product candidates; the clinical utility,
potential benefits and market acceptance of Chemomab&rsquo;s product candidates; Chemomab&rsquo;s commercialization, marketing and
manufacturing capabilities and strategy; Chemomab&rsquo;s ability to protect its intellectual property position; and the requirement
for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all.
Additional risks and uncertainties relating to Chemomab&rsquo;s and its business can be found under the caption &ldquo;Risk
Factors&rdquo; and elsewhere in Chemomab&rsquo;s filings and reports with the SEC. Chemomab expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
Chemomab&rsquo;s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements
are based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Relations:</B><BR>
Irina Koffler<BR>
LifeSci Advisors, LLC<BR>
Phone: +1-917-734-7387<FONT STYLE="background-color: yellow"><BR>
</FONT><B><U>ir@chemomab.com</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Chemomab Therapeutics:</B><BR>
Sharon Elkobi<BR>
VP, Business Development<BR>
Phone: +972773310156<BR>
<B><U>bd@chemomab.com</U></B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2116118d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2116118d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 34# 2(  A$! Q$!_\0
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MU-5>PLXM.TZVL;<$0VT20Q@G)VJ !^@JQ6+WT- HHHI %%%% !1110 4444
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MJ<=AT&/:MZLI\O,^78J-[:A1114C"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9--';PO-,ZQQH-S,Q
MP *Y\>._#IF\O[<1VW&)]OYXK'^)UY-#I]E:HQ6*=V:3'?;C /YY_"O,:]S
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
